Nano-sized platforms for vaginal drug delivery

Current Pharmaceutical Design

Volumn 21, Issue 12, 2015, Pages 1633-1644

  El Hammadi, Mazen M ^a,b   Arias, José L ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b DAMASCUS UNIVERSITY   (Syrian Arab Republic)

Author keywords

Carbon based nanostructure; Cyclodextrin; Dendrimer; Liposome; Nanoemulsion; Nanomedicine; Nanoparticle; Vaginal drug delivery

Indexed keywords

CARBON NANOTUBE; CYCLODEXTRIN DERIVATIVE; DENDRIMER; FULLERENE DERIVATIVE; LIPOSOME; NANOPARTICLE;

ARTICLE; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; NANOEMULSION; PRIORITY JOURNAL; VAGINA FLORA; VAGINA PH; VAGINAL SECRETION; ANIMAL; DRUG RELEASE; FEMALE; HUMAN; INTRAVAGINAL DRUG ADMINISTRATION; METABOLISM; NANOMEDICINE; NANOTECHNOLOGY; PROCEDURES; VAGINA;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; FEMALE; HUMANS; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; VAGINA;

EID: 84930913863     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666141029150427     Document Type: Article

References (76)

1. Acartürk F. Mucoadhesive vaginal drug delivery systems. Recent Pat Drug Deliv Formul 2009; 3: 193-205.
2. Gupta S, Gabrani R, Ali J, Dang S. Exploring novel approaches to vaginal drug delivery. Recent Pat Drug Deliv Formul 2011; 5: 82-94.
3. Vermani K, Garg S. The scope and potential of vaginal drug delivery. Pharm Sci Technolo Today 2000; 3: 359-64.
4. das Neves J, Bahia MF. Gels as vaginal drug delivery systems. Int J Pharm 2006; 318: 1-14.
5. Rohan LC, Sassi AB. Vaginal drug delivery systems for HIV prevention. AAPS J 2009; 11: 78-87.
6. Paveli Z, Skalko-Basnet N, Schubert R. Liposomal gels for vaginal drug delivery. Int J Pharm 2001; 219: 139-49.
7. Mattsson LA, Ericsson A, Bøgelund M, Maamari R. Women’s preferences toward attributes of local estrogen therapy for the treatment of vaginal atrophy. Maturitas 2013; 74: 259-63.
8. Hardy E, de Pádua KS, Hebling EM, Osis MJ, Zaneveld LJ. Women’s preferences for vaginal antimicrobial contraceptives. V: attitudes of Brazilian women to the insertion of vaginal products. Contraception 2003; 67: 391-5.
9. Hardy E, de Pádua KS, Jiménez AL, Zaneveld LJ. Women’s preferences for vaginal antimicrobial contraceptives. II. Preferred characteristics according to women’s age and socioeconomic status. Contraception 1998; 58: 239-44.
10. Hardy E, Jiménez AL, de Pádua KS, Zaneveld LJ. Women’s preferences for vaginal antimicrobial contraceptives. III. Choice of a formulation, applicator, and packaging. Contraception 1998; 58: 245-9.
11. Hardy E, de Pádua KS, Osis MJ, Jiménez AL, Zaneveld LJ. Women’s preferences for vaginal antimicrobial contraceptives. IV. Attributes of a formulation that would protect from STD/AIDS. Contraception 1998; 58: 251-5.
12. Olmsted SS, Padgett JL, Yudin AI, Whaley KJ, Moench TR, Cone RA. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys J 2001; 81: 1930-7.
13. Lai SK, O’Hanlon DE, Harrold S, et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci USA 2007; 104: 1482-7.
14. Ballou B, Andreko SK, Osuna-Highley E, et al. Nanoparticle transport from mouse vagina to adjacent lymph nodes. PLoS One 2012; 7: e51995.
15. Meng J, Sturgis TF, Youan BB. Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion. Eur J Pharm Sci 2011; 44: 57-67.
16. Alukda D, Sturgis T, Youan BB. Formulation of tenofovir-loaded functionalized solid lipid nanoparticles intended for HIV prevention. J Pharm Sci 2011; 100: 3345-56.
17. das Neves J, Rocha CM, Gonçalves MP, et al. Interactions of microbicide nanoparticles with a simulated vaginal fluid. Mol Pharm 2012; 9: 3347-56.
18. das Neves J, Michiels J, Ariën KK, et al. Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine. Pharm Res 2012; 29: 1468-84.
19. Tang BC, Dawson M, Lai SK, et al. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci USA 2009; 106: 19268-73.
20. Cu Y, Saltzman WM. Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol Pharm 2009; 6: 173-81.
21. Cu Y, Booth CJ, Saltzman WM. In vivo distribution of surfacemodified PLGA nanoparticles following intravaginal delivery. J Control Release 2011; 156: 258-64.
22. Date AA, Shibata A, Goede M, et al. Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis. Antiviral Res 2012; 96: 430-6.
23. Esposito E, Ravani L, Contado C, et al. Clotrimazole nanoparticle gel for mucosal administration. Mater Sci Eng C Mater Biol Appl 2013; 33: 411-8.
24. Yoo JW, Giri N, Lee CH. pH-sensitive Eudragit nanoparticles for mucosal drug delivery. Int J Pharm 2011; 403: 262-7.
25. Zhang T, Sturgis TF, Youan BB. pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission. Eur J Pharm Biopharm 2011; 79: 526-36.
26. Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Saltzman WM. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater 2009; 8: 526-33.
27. Palliser D, Chowdhury D, Wang QY, et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 2006; 439: 89-94.
28. Ham AS, Cost MR, Sassi AB, Dezzutti CS, Rohan LC. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm Res 2009; 26: 502-11.
29. Lara HH, Ayala-Nuñez NV, Ixtepan-Turrent L, Rodriguez-Padilla C. Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology 2010; 8: 1.
30. Lara HH, Ixtepan-Turrent L, Garza Treviño EN, Singh DK. Use of silver nanoparticles increased inhibition of cell-associated HIV-1 infection by neutralizing antibodies developed against HIV-1 envelope proteins. J Nanobiotechnology 2011; 9: 38.
31. Lara HH, Ixtepan-Turrent L, Garza-Treviño EN, Rodriguez-Padilla C. PVP-coated silver nanoparticles block the transmission of cellfree and cell-associated HIV-1 in human cervical culture. J Nanobiotechnology 2010; 8: 15.
32. Bowman MC, Ballard TE, Ackerson CJ, Feldheim DL, Margolis DM, Melander C. Inhibition of HIV fusion with multivalent gold nanoparticles. J Am Chem Soc 2008; 130: 6896-7.
33. Vijayakumar S, Ganesan S. Gold nanoparticles as an HIV entry inhibitor. Curr HIV Res 2012; 10: 643-6.
34. Paveli Z, Skalko-Basnet N, Jalsenjak I. Characterisation and in vitro evaluation of bioadhesive liposome gels for local therapy of vaginitis. Int J Pharm 2005; 301: 140-8.
35. Paveli Z, Skalko-Basnet N, Jalsenjak I. Liposomes containing drugs for treatment of vaginal infections. Eur J Pharm Sci 1999; 8: 345-51.
36. Paveli Z, Skalko-Basnet N, Jalsenjak I. Liposomal gel with chloramphenicol: characterisation and in vitro release. Acta Pharm 2004; 54: 319-30.
37. Kang JW, Davaa E, Kim YT, Park JS. A new vaginal delivery system of amphotericin B: a dispersion of cationic liposomes in a thermosensitive gel. J Drug Target 2010; 18: 637-44.
38. Ning MY, Guo YZ, Pan HZ, Yu HM, Gu ZW. Preparation and evaluation of proliposomes containing clotrimazole. Chem Pharm Bull (Tokyo) 2005; 53: 620-4.
39. Li WZ, Zhao N, Zhou YQ, et al. Post-expansile hydrogel foam aerosol of PG-liposomes: a novel delivery system for vaginal drug delivery applications. Eur J Pharm Sci 2012; 47: 162-9.
40. Basnet P, Hussain H, Tho I, Skalko-Basnet N. Liposomal delivery system enhances anti-inflammatory properties of curcumin. J Pharm Sci 2012; 101: 598-609.
41. Gupta PN, Pattani A, Curran RM, et al. Development of liposome gel based formulations for intravaginal delivery of the recombinant HIV-1 envelope protein CN54gp140. Eur J Pharm Sci 2012; 46: 315-22.
42. Chen D, Sun K, Mu H, et al. pH and temperature dual-sensitive liposome gel based on novel cleavable mPEG-Hz-CHEMS polymeric vaginal delivery system. Int J Nanomedicine 2012; 7: 2621-30.
43. Jiménez JL, Pion M, de la Mata FJ, et al. Dendrimers as topical microbicides with activity against HIV. New J Chem 2012; 36: 299-309.
44. Dutta T, Jain NK. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim Biophys Acta 2007; 1770: 681-6.
45. Dutta T, Garg M, Jain NK. Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro. Eur J Pharm Sci 2008; 34: 181-9.
46. Rupp R, Rosenthal SL, Stanberry LR. VivaGel (SPL7013 Gel): a candidate dendrimer--microbicide for the prevention of HIV and HSV infection. Int J Nanomedicine 2007; 2: 561-6.
47. Gong E, Matthews B, McCarthy T, et al. Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses. Antiviral Res 2005; 68: 139-46.
48. Patton DL, Cosgrove Sweeney YT, McCarthy TD, Hillier SL. Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model. Antimicrob Agents Chemother 2006; 50: 1696-700.
49. McCarthy TD, Karellas P, Henderson SA, et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm 2005; 2: 312-8.
50. Price CF, Tyssen D, Sonza S, et al. SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS One 2011; 6: e24095.
51. Sepúlveda-Crespo D, Lorente R, Leal M, et al. Synergistic activity profile of carbosilane dendrimer G2-STE16 in combination with other dendrimers and antiretrovirals as topical anti-HIV-1 microbicide. Nanomedicine 2013; 10: 609-18.
52. Vacas Córdoba E, Arnaiz E, Relloso M, et al. Development of sulphated and naphthylsulphonated carbosilane dendrimers as topical microbicides to prevent HIV-1 sexual transmission. AIDS 2013; 27: 1219-29.
53. Wang B, Navath RS, Menjoge AR, et al. Inhibition of bacterial growth and intramniotic infection in a guinea pig model of chorioamnionitis using PAMAM dendrimers. Int J Pharm 2010; 395: 298-308.
54. Blanzat M, Turrin CO, Aubertin AM, et al. Dendritic catanionic assemblies: in vitro anti-HIV activity of phosphorus-containing dendrimers bearing galbeta1cer analogues. Chembiochem 2005; 6: 2207-13.
55. D’Cruz OJ, Uckun FM. Gel-microemulsions as vaginal spermicides and intravaginal drug delivery vehicles. Contraception 2001; 64: 113-23.
56. D’Cruz OJ, Uckun FM. Influence of long-term stability conditions on microbicidal nucleoside prodrug (WHI-07)-loaded gelmicroemulsion. AAPS PharmSciTech 2006; 7: 73.
57. D’Cruz OJ, Uckun FM. Preclinical evaluation of a dual-acting microbicidal prodrug WHI-07 in combination with vanadocene dithiocarbamate in the female reproductive tract of rabbit, pig, and cat. Toxicol Pathol 2007; 35: 910-27.
58. Bachhav YG, Patravale VB. Microemulsion-based vaginal gel of clotrimazole: formulation, in vitro evaluation, and stability studies. AAPS PharmSciTech 2009; 10: 476-81.
59. Mirza MA, Ahmad S, Mallick MN, Manzoor N, Talegaonkar S, Iqbal Z. Development of a novel synergistic thermosensitive gel for vaginal candidiasis: an in vitro, in vivo evaluation. Colloids Surf B Biointerfaces 2013; 103: 275-82.
60. Bakry R, Vallant RM, Najam-ul-Haq M, Rainer M, Szabo Z, Huck CW, Bonn GK. Medicinal applications of fullerenes. Int J Nanomedicine 2007; 2(4): 639-49.
61. Xu X, Wang X, Li Y, Wang Y, Yang L. A large-scale association study for nanoparticle C60 uncovers mechanisms of nanotoxicity disrupting the native conformations of DNA/RNA. Nucleic Acids Res 2012; 40: 7622-32.
62. Marchesan S, Da Ros T, Spalluto G, Balzarini J, Prato M. Anti-HIV properties of cationic fullerene derivatives. Bioorg Med Chem Lett 2005; 15: 3615-8.
63. Meher BR, Wang Y. Binding of single walled carbon nanotube to WT and mutant HIV-1 proteases: analysis of flap dynamics and binding mechanism. J Mol Graph Model 2012; 38: 430-45.
64. Aschberger K, Johnston HJ, Stone V, et al. Review of carbon nanotubes toxicity and exposure--appraisal of human health risk assessment based on open literature. Crit Rev Toxicol 2010; 40: 759-90.
65. Sharma N, Baldi A. Exploring versatile applications of cyclodextrins: an overview. Drug Deliv 2014; 22: 1-19.
66. Francois M, Snoeckx E, Putteman P, et al. A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole. AAPS PharmSci 2003; 5: E5.
67. Cevher E, Açma A, Sinani G, Aksu B, Zloh M, Mülazimoğlu L. Bioadhesive tablets containing cyclodextrin complex of itraconazole for the treatment of vaginal candidiasis. Int J Biol Macromol 2014; 69: 124-36.
68. Bilensoy E, Rouf MA, Vural I, Hincal AA. Thermosensitive vaginal gel formulation for the controlled release of clotrimazole via complexation to beta-cyclodextrin. J Control Release 2006; 116: e107-9.
69. Cevher E, Sensoy D, Zloh M, Mülazimolu L. Preparation and characterisation of natamycin: gamma-cyclodextrin inclusion complex and its evaluation in vaginal mucoadhesive formulations. J Pharm Sci 2008; 97: 4319-35.
70. Kima YT, Shina BK, Garripellib VK, et al. A thermosensitive vaginal gel formulation with HP CD for the pH-dependent release and solubilization of amphotericin B. Eur J Pharm Sci 2010; 41: 399-406.
71. Demirel M, Yurtda G, Genç L. Inclusion complexes of ketoconazole with beta-cyclodextrin: physicochemical characterization and in vitro dissolution behaviour of its vaginal suppositories. J Incl Phenom Macro 2011; 70: 437-45.
72. Bilensoy E, Çirpanli Y, Şen M, Lale Doğan AL, Çaliş S. Thermosensitive mucoadhesive gel formulation loaded with 5-Fu: cyclodextrin complex for HPV-induced cervical cancer. J Incl Phenom Macro 2007; 57: 363-70.
73. Yang H, Parniak MA, Isaacs CE, Hillier SL, Rohan LC. Characterization of cyclodextrin inclusion complexes of the anti-HIV nonnucleoside reverse transcriptase inhibitor UC781. AAPS J 2008; 10: 606-13.
74. Zhou Q, Zhong L, Wei X, Dou W, Chou G, Wang Z. Baicalein and hydroxypropyl-γ-cyclodextrin complex in poloxamer thermal sensitive hydrogel for vaginal administration. Int J Pharm 2013; 454: 125-34.
75. Ambrose Z, Compton L, Piatak M Jr, et al. Incomplete protection against simian immunodeficiency virus vaginal transmission in rhesus macaques by a topical antiviral agent revealed by repeat challenges. J Virol 2008; 82: 6591-9.
76. Değim Z, Değim T, Acartürk F, Erdoğan D, Ozoğul C, Köksal M. Rectal and vaginal administration of insulin-chitosan formulations: an experimental study in rabbits. J Drug Target 2005; 13: 563-72.